Genedata Selector 7.0 リリース：
Automating Complex NGS-based Workflows for Biosafety Testing from Assay Development to Monitoring throughout Scale-Up and Production
April 28, 2021
Genedata, the leading provider of enterprise software for biopharmaceutical R&D, today announced a new release of its first-in-class Genedata Selector® software platform that enables the automation of complex next-generation sequencing (NGS) based workflows. The new release Genedata Selector 7.0 provides important new functionalities that automate the detection of adventitious agents and the assessment of cell line stability. Coupled with scientific domain expertise, Genedata is well-positioned to address the growing demands of the biopharmaceutical industry related to the digitalization of NGS-based workflows from early cell line engineering to late quality and biosafety testing.
Genedata Selector enables customers to perform NGS-based biosafety in-house rather than outsourcing to external providers and thus streamlines the entire biosafety testing process. With Genedata Selector, results can be generated in hours rather than weeks. More and more leading biopharmaceutical companies are now adopting Genedata Selector for biosafety assessment and quality control due to its efficient data management, unique data integration, and scalable data analysis capabilities. The adoption of the software provides a higher throughput and ultimately results in reduced costs per tested sample, while enabling biopharmaceutical companies to protect their valuable IP.
Beyond software, Genedata provides consulting services in support of developing NGS-based assays for biosafety testing.
Release 7.0 of Genedata Selector strengthens:
- Cell Line Heterogeneity and Stability Analysis with a new functionality based on single-cell RNA sequencing (scRNA-Seq), which can be combined with variant analysis capabilities to assess cell line stability.
- Process Transparency and Control, by providing new comprehensive overviews of activities related to ongoing processes, and new playbooks (step-by-step guided interfaces), which enable greater insight on data analysis, sample tracking, and reporting. In particular, these new features support internal release processes, as well as automation and compliance requirements.
- Data Security, enabling the tracking of samples and full control of user access to data during the whole analytical process, which is particularly important for IP protection and regulatory compliance.
- Team Onboarding and Collaboration, through enhanced user interfaces that enable efficient collaboration between different users and sharing of data across functional units. This also accelerates the onboarding of new team members.
In addition to quality monitoring, biopharmaceutical companies are also leveraging Genedata Selector to streamline all their NGS-related workflows in cell line development and bioprocess optimization. This allows companies to track all their NGS and related data throughout the entire development process in a secure, transparent, in-house system.
“With Genedata Selector, our focus is on eliminating major bottlenecks in biopharmaceutical development by automating complex NGS-based workflows” said Dr Othmar Pfannes, CEO of Genedata. “With this latest release, we have made a major step forward in streamlining a key workflow in assessing the biosafety of innovative biotherapeutics. With Genedata Selector, we remain committed to continuously improving other NGS-based workflows to support the biopharmaceutical industry in their goal to become more efficient in their R&D processes.“
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.